Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FEMY NASDAQ:IMVT NASDAQ:SLNO NYSE:SOLV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFEMYFemasys$0.61+5.4%$0.49$0.31▼$1.80$19.83M-2.641.92 million shs1.74 million shsIMVTImmunovant$18.74-0.8%$16.12$12.72▼$32.10$3.27B0.481.52 million shs1.30 million shsSLNOSoleno Therapeutics$63.66-4.8%$64.16$41.50▼$90.32$3.38B-2.751.29 million shs884,219 shsSOLVSolventum$72.30-0.6%$72.64$60.70▼$85.92$12.54B0.51.08 million shs692,306 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFEMYFemasys-9.57%+4.89%+59.80%-36.90%-55.23%IMVTImmunovant-1.72%+5.41%+21.23%+3.17%-36.15%SLNOSoleno Therapeutics-0.34%-1.14%+18.24%-24.00%+24.72%SOLVSolventum-0.24%+1.47%-1.44%-1.68%+0.16%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFEMYFemasys$0.61+5.4%$0.49$0.31▼$1.80$19.83M-2.641.92 million shs1.74 million shsIMVTImmunovant$18.74-0.8%$16.12$12.72▼$32.10$3.27B0.481.52 million shs1.30 million shsSLNOSoleno Therapeutics$63.66-4.8%$64.16$41.50▼$90.32$3.38B-2.751.29 million shs884,219 shsSOLVSolventum$72.30-0.6%$72.64$60.70▼$85.92$12.54B0.51.08 million shs692,306 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFEMYFemasys-9.57%+4.89%+59.80%-36.90%-55.23%IMVTImmunovant-1.72%+5.41%+21.23%+3.17%-36.15%SLNOSoleno Therapeutics-0.34%-1.14%+18.24%-24.00%+24.72%SOLVSolventum-0.24%+1.47%-1.44%-1.68%+0.16%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFEMYFemasys 2.50Moderate Buy$7.331,104.75% UpsideIMVTImmunovant 2.58Moderate Buy$28.7853.56% UpsideSLNOSoleno Therapeutics 2.93Moderate Buy$115.9282.09% UpsideSOLVSolventum 2.33Hold$84.8917.41% UpsideCurrent Analyst Ratings BreakdownLatest SLNO, FEMY, IMVT, and SOLV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025IMVTImmunovantTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageHold$16.0010/14/2025IMVTImmunovantWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025FEMYFemasysWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025SLNOSoleno TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025SOLVSolventumWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)10/7/2025SLNOSoleno TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$125.0010/7/2025SLNOSoleno TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$125.0010/1/2025SOLVSolventumUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$77.0010/1/2025SOLVSolventumUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$77.009/30/2025IMVTImmunovantJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$37.00 ➝ $33.009/27/2025FEMYFemasysWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 10/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFEMYFemasys$1.63M12.17N/AN/A$0.10 per share6.09IMVTImmunovantN/AN/AN/AN/A$4.16 per shareN/ASLNOSoleno TherapeuticsN/AN/AN/AN/A$5.68 per shareN/ASOLVSolventum$8.25B1.52$9.85 per share7.34$17.13 per share4.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFEMYFemasys-$18.82M-$0.86N/AN/AN/A-1,113.72%-713.74%-152.60%11/11/2025 (Estimated)IMVTImmunovant-$413.84M-$2.85N/AN/AN/AN/A-80.99%-72.23%11/6/2025 (Estimated)SLNOSoleno Therapeutics-$175.85M-$4.14N/AN/AN/AN/A-73.74%-56.67%11/4/2025 (Estimated)SOLVSolventum$478M$2.1633.4713.172.974.52%29.93%6.65%11/6/2025 (Estimated)Latest SLNO, FEMY, IMVT, and SOLV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025N/AFEMYFemasys-$0.12N/AN/AN/AN/AN/A11/6/2025Q2 2026IMVTImmunovant-$0.73N/AN/AN/AN/AN/A11/6/2025Q3 2025SOLVSolventum$1.41N/AN/AN/A$2.05 billionN/A11/5/2025Q3 2025SLNOSoleno Therapeutics$0.08N/AN/AN/A$47.46 millionN/A8/11/2025Q1 2026IMVTImmunovant-$0.69-$0.60+$0.09-$0.71N/AN/A8/8/2025Q2 2025FEMYFemasys-$0.18-$0.16+$0.02-$0.16$0.80 million$0.41 million8/7/2025Q2 2025SOLVSolventum$1.45$1.69+$0.24$0.51$2.12 billion$2.16 billion8/6/2025Q2 2025SLNOSoleno Therapeutics-$0.53-$0.09+$0.44-$0.09$3.91 million$32.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFEMYFemasysN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/ASLNOSoleno TherapeuticsN/AN/AN/AN/AN/ASOLVSolventumN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFEMYFemasys0.030.890.41IMVTImmunovantN/A12.3212.32SLNOSoleno Therapeutics0.2115.1315.01SOLVSolventum2.141.220.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFEMYFemasys65.27%IMVTImmunovant47.08%SLNOSoleno Therapeutics97.42%SOLVSolventumN/AInsider OwnershipCompanyInsider OwnershipFEMYFemasys11.54%IMVTImmunovant1.80%SLNOSoleno Therapeutics6.40%SOLVSolventum0.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFEMYFemasys3032.58 million28.82 millionNot OptionableIMVTImmunovant120174.32 million171.18 millionOptionableSLNOSoleno Therapeutics3053.15 million49.74 millionOptionableSOLVSolventum22,000173.39 million173.30 millionOptionableSLNO, FEMY, IMVT, and SOLV HeadlinesRecent News About These CompaniesAllianz Asset Management GmbH Raises Stock Position in Solventum Corporation $SOLVOctober 23 at 4:28 AM | marketbeat.comSolventum: A Solid Performance HereOctober 22 at 1:03 PM | seekingalpha.comSOLV or MEDP: Which Is the Better Value Stock Right Now?October 22 at 12:41 PM | zacks.comSolventum names Heather Knight chief commercial officerOctober 22 at 2:08 AM | msn.comSolventum hires Baxter EVP and COO Heather Knight for new C-suite roleOctober 21 at 7:49 PM | massdevice.comSolventum Appoints Heather Knight as Chief Commercial OfficerOctober 21 at 5:31 PM | tipranks.comSolventum Appoints Heather Knight as Chief Commercial OfficerOctober 21 at 5:00 PM | prnewswire.comSygnia Itrix MSCI US ETF Sees Index Constituent UpdateOctober 20 at 10:02 AM | msn.comSolventum Corp Added to Sygnia Itrix ETF Following Index RebalancingOctober 20 at 10:02 AM | msn.comNordea Investment Management AB Has $55.49 Million Stock Position in Solventum Corporation $SOLVOctober 19, 2025 | marketbeat.comGenerali Asset Management SPA SGR Lowers Stock Position in Solventum Corporation $SOLVOctober 19, 2025 | marketbeat.comSolventum to Report Third Quarter Fiscal 2025 Earnings on November 6, 2025October 16, 2025 | prnewswire.comSolventum (SOLV): Is There Value After Recent Momentum Shift?October 15, 2025 | finance.yahoo.comCypress Capital Group Boosts Stake in Solventum Corporation $SOLVOctober 13, 2025 | marketbeat.comSolventum Corporation (NYSE:SOLV) Receives Consensus Recommendation of "Hold" from AnalystsOctober 12, 2025 | americanbankingnews.comSolventum Corporation (NYSE:SOLV) Receives Consensus Recommendation of "Hold" from BrokeragesOctober 12, 2025 | marketbeat.comStrong Tower Advisory Services Raises Stake in Solventum Corporation $SOLVOctober 11, 2025 | marketbeat.comUS Bancorp DE Sells 21,641 Shares of Solventum Corporation $SOLVOctober 11, 2025 | marketbeat.comKLP Kapitalforvaltning AS Has $4.70 Million Stock Position in Solventum Corporation $SOLVOctober 11, 2025 | marketbeat.com3M to sell Solventum shares for $648 million in secondary offeringOctober 10, 2025 | investing.comMirae Asset Global Investments Co. Ltd. Sells 38,748 Shares of Solventum Corporation $SOLVOctober 10, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSLNO, FEMY, IMVT, and SOLV Company DescriptionsFemasys NASDAQ:FEMY$0.61 +0.03 (+5.40%) Closing price 04:00 PM EasternExtended Trading$0.61 +0.00 (+0.38%) As of 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.Immunovant NASDAQ:IMVT$18.74 -0.16 (-0.85%) Closing price 04:00 PM EasternExtended Trading$19.17 +0.43 (+2.29%) As of 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Soleno Therapeutics NASDAQ:SLNO$63.66 -3.24 (-4.84%) Closing price 04:00 PM EasternExtended Trading$64.13 +0.47 (+0.74%) As of 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.Solventum NYSE:SOLV$72.30 -0.46 (-0.63%) Closing price 03:59 PM EasternExtended Trading$72.28 -0.03 (-0.04%) As of 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 GM Posts Largest Gain Since the Pandemic: Shares Still Look Cheap 3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
